Stefan C Bertog1,2, Nathan A Sobotka2, Paul A Sobotka3,4, Melvin D Lobo5, Kolja Sievert1, Laura Vaskelyte1, Horst Sievert1, Roland E Schmieder6. 1. CardioVascular Center, Frankfurt, Germany. 2. St Paul Academy and Summit School, St Paul, MN, USA. 3. ROX Medical Inc., San Clemente, CA, USA. 4. Department of Medicine, Division of Cardiology, The Ohio State University, Columbus, OH, USA. 5. NIHR Biomedical Research Centre at Barts, Barts Health NHS Trust and Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. 6. Department of Nephrology and Hypertension, University Hospital, Friedrich-Alexander University Erlangen-Nuremberg, Ulmenweg 18, 91054, Erlangen, Germany. roland.schmieder@uk-erlangen.de.
Abstract
PURPOSE OF REVIEW: Provision of a summary on the physiologic effects of arteriovenous fistula creation and description of previously published human data on the efficacy of a percutaneously implanted device creating an arteriovenous fistula. Though antihypertensive therapy is effective, some patient's blood pressure remains poorly controlled despite adherence to optimal medical therapy. Moreover, some patients are not compliant with recommended medical therapy due to side effects or personal decision. This has prompted exploration of alternative, device-based antihypertensive therapies including, among others, the percutaneous creation of an arteriovenous fistula. An arteriovenous fistula is accompanied by a number of favorable physiologic changes that may lower blood pressure. These physiologic changes, conduction of the procedure, and previously published human experience are summarized in this review article. RECENT FINDINGS: The results of a recently published trial comparing arteriovenous fistula creation and standard antihypertensive therapy versus standard antihypertensive therapy alone are summarized. Creation of an arteriovenous fistula is accompanied by a significant blood pressure reduction likely related to a reduction in total arterial resistance, perhaps blood volume reduction, inhibition of the baroreceptor reflex, and release of natriuretic peptides. These findings foster further interest in studying the impact of an arteriovenous fistula and arterial blood pressure. The design of a large randomized trial comparing arteriovenous fistula creation to sham control is outlined.
PURPOSE OF REVIEW: Provision of a summary on the physiologic effects of arteriovenous fistula creation and description of previously published human data on the efficacy of a percutaneously implanted device creating an arteriovenous fistula. Though antihypertensive therapy is effective, some patient's blood pressure remains poorly controlled despite adherence to optimal medical therapy. Moreover, some patients are not compliant with recommended medical therapy due to side effects or personal decision. This has prompted exploration of alternative, device-based antihypertensive therapies including, among others, the percutaneous creation of an arteriovenous fistula. An arteriovenous fistula is accompanied by a number of favorable physiologic changes that may lower blood pressure. These physiologic changes, conduction of the procedure, and previously published human experience are summarized in this review article. RECENT FINDINGS: The results of a recently published trial comparing arteriovenous fistula creation and standard antihypertensive therapy versus standard antihypertensive therapy alone are summarized. Creation of an arteriovenous fistula is accompanied by a significant blood pressure reduction likely related to a reduction in total arterial resistance, perhaps blood volume reduction, inhibition of the baroreceptor reflex, and release of natriuretic peptides. These findings foster further interest in studying the impact of an arteriovenous fistula and arterial blood pressure. The design of a large randomized trial comparing arteriovenous fistula creation to sham control is outlined.
Authors: Manish Saxena; Paul A Sobotka; Stephen M Hamshere; Ajay Jain; Anthony Mathur; Charles Knight; David J Collier; Melvin D Lobo Journal: Circ Cardiovasc Interv Date: 2016-08 Impact factor: 6.546
Authors: John P Foran; Ajay K Jain; Ivan P Casserly; David E Kandzari; Krishna J Rocha-Singh; Adam Witkowski; Barry T Katzen; David Deaton; Peter Balmforth; Paul A Sobotka Journal: Catheter Cardiovasc Interv Date: 2014-11-01 Impact factor: 2.692
Authors: Vikas Kapil; Paul A Sobotka; Manish Saxena; Anthony Mathur; Charles Knight; Eamon Dolan; Alice Stanton; Melvin D Lobo Journal: Curr Hypertens Rep Date: 2015-09 Impact factor: 5.369
Authors: John S Clemmer; W Andrew Pruett; Robert L Hester; Thomas E Lohmeier Journal: Am J Physiol Heart Circ Physiol Date: 2019-08-30 Impact factor: 4.733
Authors: Roy O Mathew; Jerome Fleg; Janani Rangaswami; Bo Cai; Arif Asif; Mandeep S Sidhu; Sripal Bangalore Journal: Am J Hypertens Date: 2019-08-14 Impact factor: 2.689
Authors: Juan Carlos Yugar-Toledo; Heitor Moreno Júnior; Miguel Gus; Guido Bernardo Aranha Rosito; Luiz César Nazário Scala; Elizabeth Silaid Muxfeldt; Alexandre Alessi; Andrea Araújo Brandão; Osni Moreira Filho; Audes Diógenes de Magalhães Feitosa; Oswaldo Passarelli Júnior; Dilma do Socorro Moraes de Souza; Celso Amodeo; Weimar Kunz Sebba Barroso; Marco Antônio Mota Gomes; Annelise Machado Gomes de Paiva; Eduardo Costa Duarte Barbosa; Roberto Dischinger Miranda; José Fernando Vilela-Martin; Wilson Nadruz Júnior; Cibele Isaac Saad Rodrigues; Luciano Ferreira Drager; Luiz Aparecido Bortolotto; Fernanda Marciano Consolim-Colombo; Márcio Gonçalves de Sousa; Flávio Antonio de Oliveira Borelli; Sérgio Emanuel Kaiser; Gil Fernando Salles; Maria de Fátima de Azevedo; Lucélia Batista Neves Cunha Magalhães; Rui Manoel Dos Santos Póvoa; Marcus Vinícius Bolívar Malachias; Armando da Rocha Nogueira; Paulo César Brandão Veiga Jardim; Thiago de Souza Veiga Jardim Journal: Arq Bras Cardiol Date: 2020 May-Jun Impact factor: 2.000